News | January 27, 2025
Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
This approval is a significant achievement in expanding the availability of this critical therapeutic,
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Subscribe To Our Newsletter & Stay Updated
